ANN ARBOR, Mich., Jan. 18, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will host an Alzheimer’s disease-focused Investor Day on Tuesday, February 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington Court Hotel in Ann Arbor, Michigan. Headquartered in Ann Arbor, Adeona’s management team welcomes shareholders, potential investors and interested parties to join them for this scientific and corporate update of the Company.
Keynote speaker, George J. Brewer, M.D., Chairman of Adeona’s Scientific Advisory Board and the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan, will provide a scientific overview of the roles zinc deficiency and copper toxicity play in patients with Alzheimer’s disease and mild cognitive impairment. After the scientific update, James S. Kuo, M.D., M.B.A.., Adeona’s Chairman and CEO, will provide an investor update that includes the Company’s near-term plans for its zinc-based therapy for Alzheimer’s disease and mild cognitive impairment that is being developed as a prescription medical food. The webcast of these presentations will be accessible via the event section on the home page of Adeona’s website at www.adeonapharma.com.
Adeona’s management team will greet guests during a reception from 3:00-3:45 P.M., with the scientific and corporate presentations to follow. Attendance at Adeona’s Investor Day is limited due to seating availability. People interested in registering to attend should contact the Company by email at investorday@adeonapharma.com or by phone at (734) 332-7800.
The Kensington Court Hotel is located near I-94 and South State Street (Exit #177) along the Briarwood Shopping Mall circle, only 2.5 miles from downtown Ann Arbor and the University of Michigan, and 25 miles from Detroit Metropolitan Airport. The hotel address is: 610 Hilton Blvd., Ann Arbor, MI. 48108.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company’s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer’s disease, and drugs for multiple sclerosis, fibromyalgia, rheumatoid arthritis and age-related macular degeneration. For more information, please visit Adeona’s website at www.adeonapharma.com.
This release includes forward-looking statements on Adeona’s current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing and results of our clinical study and our ability to successfully develop products with superior benefits. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona’s forward-looking statements include, among others, a failure of our clinical trials to be completed on time or to achieve desired results, a failure of our clinical reference laboratory to continue to grow and achieve revenue or a failure by us or our strategic partners to successfully commercialize products and other factors described in Adeona’s report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.
